• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Swan Joseph increased direct ownership by 5,079% to 51,793 units (SEC Form 5)

    8/2/24 6:10:16 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IXHL alert in real time by email
    SEC FORM 5 SEC Form 5
    FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0362
    Estimated average burden
    hours per response: 1.0
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Form 3 Holdings Reported.
    X
    Form 4 Transactions Reported.
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Swan Joseph

    (Last) (First) (Middle)
    105 / 8 CENTURY CIRCUIT

    (Street)
    NORWEST, NEW SOUTH WALES C3 2153

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Incannex Healthcare Inc. [ IXHL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CFO, Treasurer and Secretary
    3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
    06/30/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Amount (A) or (D) Price
    Restricted Shares of Common Stock 05/06/2024(1) A4(2) 50,793 A $0 51,793 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Award of restricted shares of which 16,931 restricted shares vested on June 30, 2024, 16,931 restricted shares will vest on June 30, 2025, and 16,931 restricted shares will vest on June 30, 2026, provided the Reporting Person is still employed on each vesting date.
    2. This Form 5 reports the award of 50,793 restricted shares by the Reporting Person pursuant to the Company's Equity Incentive Plan occurred on May 6, 2024.
    /s/ Joseph Swan 08/02/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IXHL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IXHL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IXHL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Barbato Luigi M. was granted 100,476 shares (SEC Form 4)

      4 - Incannex Healthcare Inc. (0001873875) (Issuer)

      10/24/24 4:49:53 PM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Barbato Luigi M.

      3 - Incannex Healthcare Inc. (0001873875) (Issuer)

      10/24/24 4:48:47 PM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Swan Joseph increased direct ownership by 5,079% to 51,793 units (SEC Form 5)

      5 - Incannex Healthcare Inc. (0001873875) (Issuer)

      8/2/24 6:10:16 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IXHL
    SEC Filings

    See more
    • Incannex Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Incannex Healthcare Inc. (0001873875) (Filer)

      6/18/25 7:30:21 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Incannex Healthcare Inc. (0001873875) (Filer)

      6/17/25 7:30:37 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Incannex Healthcare Inc. (0001873875) (Filer)

      6/13/25 6:09:53 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IXHL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

      NEW YORK and MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, is pleased to announce that it has achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea (OSA), on schedule as of 16 June 2025. This marks a major milestone in the development of IHL-42X, confirming the completion of clinical data collection and enabling final statistical analysis to begin. The Company is on track to deliver top-line results in July 2025, reinforcing confide

      6/18/25 7:30:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy

      NEW YORK and MELBOURNE, Australia, June 17, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces entering into a 50:50 joint venture with Mind Medicine Australia ("MMA") to operate a psychedelic-assisted therapies services clinic in Melbourne. Incannex CEO Joel Latham commented, "This joint venture is a significant milestone around our strategy to bring psychedelic-assisted therapies to those who need them most. Working alongside a leading organization in this space, we expect to build the clinical infrastructure necessary to deli

      6/17/25 7:30:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

      NEW YORK and MELBOURNE, Australia, June 12, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces it has successfully canceled all remaining Series A Warrants pursuant to its letter agreements with the holders of the Series A Warrants, having raised the full amount of capital required to complete the cancellation through its At-The-Market ("ATM") facility. This follows the Company's May 28, 2025, announcement of binding agreements to cancel the final 172 million Series A Warrants in exchange for $12.2 million. Combined with a tranc

      6/12/25 7:30:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IXHL
    Leadership Updates

    Live Leadership Updates

    See more
    • Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

      NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board: Scott A. Sands, Ph.D., Associate Professor of Medicine at Harvard Medical School and Director of the Sleep Apnea Translational Physiology Group in the Division of Sleep and Circadian Disorders at Brigham and Women's Hospital.Ali Azarbarzin, Ph.D., Associate Professor of Medicine at Harvard Medical School and a lead

      6/3/25 7:30:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

      NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended March 31, 2025. "The third quarter of 2025 represents a pivotal period of progress for Incannex as we continue to execute on our IHL-42X development program," said Joel Latham, President and CEO of Incannex. "With the rapid completion of Phase 2 enrollment in the Phase 2/3 RePOSA, recent positive and confirmatory PK and safety clinical results, and the addition of

      5/15/25 8:00:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

      Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms, Representing ResMed NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended December 31, 2024. "Patients with obstructive sleep apnea need new and convenient therapeutic options to manage this serious, chroni

      2/14/25 7:30:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IXHL
    Financials

    Live finance-specific insights

    See more
    • Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

      MELBOURNE, Australia, July 27, 2022 /PRNewswire/ -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ:IXHL), ('Incannex' or the 'Company'), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 June 2022. Incannex is undertaking a multitude of U.S. Food and Drug Administration ('FDA') programs for cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health professionals. Cannabinoid IHL-42X: positive phase 2a clinical trial results in patients with obstructive sleep apnoea In June 2022, Incannex announced positive results from full analysis of its phase 2 clinical trial o

      7/27/22 7:55:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quarterly Activities Report and Appendix 4C Cash Flow Statement

      Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea Index ('AHI') 20% of IHL-42X clinical trial participants experienced a reduction in AHI of greater than 80% completes comprehensive in vivo study on the neuroprotective capability of IHL-216A with results being analysed to be released within 2-3 weeks treatment commences in the phase 2a clinical trial to assess psilocybin and specialised psychotherapy for the treatment of generalised anxiety disorder initiates a second clinical psychedelic therapy program in a leading-edge academic field of virtual reality (VR) exposure response therapy

      4/28/22 7:55:00 AM ET
      $IXHL
      Biotechnology: Pharmaceutical Preparations
      Health Care